市場調查報告書
商品編碼
994782

稀少血友病因子的全球市場

Rare Hemophilia Factors

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 130 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球稀少血友病因子的市場規模,預計在分析期間(2020年∼2027年)將以4.8%的年複合成長率增長,從2020年的2億5,230萬美元,到2027年達到3億5,080萬美元。

本報告所分析的市場區隔之一的新鮮凍結血漿部門,在分析期間中預計將以4.7%的年複合成長率增長,達到1億6,810萬美元。

本報告提供全球稀少血友病因子市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Baxalta
  • Bayer healthcare
  • Bio Products Laboratory Ltd
  • Biogen
  • CSL Behring
  • Novo Nordisk
  • Pfizer, Inc.
  • Shire
  • Takeda Pharmaceutical Co. Ltd.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
    • 競爭的市場佔有率:各市場區隔
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:40公司
目錄
Product Code: MCP22683

Abstract:

Global Rare Hemophilia Factors Market to Reach $350.8 Million by 2027

Amid the COVID-19 crisis, the global market for Rare Hemophilia Factors estimated at US$252.3 Million in the year 2020, is projected to reach a revised size of US$350.8 Million by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027. Fresh Frozen Plasma, one of the segments analyzed in the report, is projected to record a 4.7% CAGR and reach US$168.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Factor Concentrates segment is readjusted to a revised 5.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $74.3 Million, While China is Forecast to Grow at 4.6% CAGR

The Rare Hemophilia Factors market in the U.S. is estimated at US$74.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$62.3 Million by the year 2027 trailing a CAGR of 4.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 4.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Cryoprecipitate Segment to Record 4.2% CAGR

In the global Cryoprecipitate segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$34.6 Million in the year 2020 will reach a projected size of US$46.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$39.3 Million by the year 2027.

Select Competitors (Total 40 Featured) -

  • Baxalta
  • Bayer healthcare
  • Bio Products Laboratory Ltd
  • Biogen
  • CSL Behring
  • Novo Nordisk
  • Pfizer, Inc.
  • Shire
  • Takeda Pharmaceutical Co. Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Rare Hemophilia Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Rare Hemophilia Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Rare Hemophilia Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Fresh Frozen Plasma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Fresh Frozen Plasma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Fresh Frozen Plasma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Factor Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Cryoprecipitate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Cryoprecipitate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Cryoprecipitate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 16: USA Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 17: USA Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: USA 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 19: Canada Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Canada Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: Canada 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 22: Japan Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: Japan Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: Japan 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 25: China Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: China Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: China 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 28: Europe Current & Future Analysis for Rare Hemophilia Factors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 29: Europe Historic Review for Rare Hemophilia Factors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Europe 15-Year Perspective for Rare Hemophilia Factors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 31: Europe Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Europe Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: Europe 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 34: France Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: France Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: France 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 37: Germany Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Germany Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: Germany 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 40: Italy Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Italy Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: Italy 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 43: UK Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: UK Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: UK 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 46: Rest of Europe Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Rest of Europe Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Rest of Europe 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 49: Asia-Pacific Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Asia-Pacific Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Asia-Pacific 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 52: Rest of World Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Rest of World Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Rest of World 15-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 40